417 related articles for article (PubMed ID: 31843999)
1.
Morrissey I; Olesky M; Hawser S; Lob SH; Karlowsky JA; Corey GR; Bassetti M; Fyfe C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843999
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Zhanel GG; Baxter MR; Adam HJ; Sutcliffe J; Karlowsky JA
Diagn Microbiol Infect Dis; 2018 May; 91(1):55-62. PubMed ID: 29338931
[TBL] [Abstract][Full Text] [Related]
3.
Morrissey I; Hawser S; Lob SH; Karlowsky JA; Bassetti M; Corey GR; Olesky M; Newman J; Fyfe C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843997
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
[TBL] [Abstract][Full Text] [Related]
5.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.
Livermore DM; Mushtaq S; Warner M; Woodford N
Antimicrob Agents Chemother; 2016 Jun; 60(6):3840-4. PubMed ID: 27044556
[TBL] [Abstract][Full Text] [Related]
8. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020.
Hawser S; Kothari N; Monti F; Morrissey I; Siegert S; Hodges T
J Glob Antimicrob Resist; 2023 Jun; 33():304-320. PubMed ID: 37207925
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China.
Zhao C; Wang X; Zhang Y; Wang R; Wang Q; Li H; Wang H
BMC Infect Dis; 2019 Jun; 19(1):508. PubMed ID: 31182038
[TBL] [Abstract][Full Text] [Related]
12. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
14.
Chen J; Liu Y; Jia W; Xu X; Sun G; Wang T; Li J; Zhang G; Jing R; Sun H; Xu Y; Liu Y
Microbiol Spectr; 2023 Jun; 11(3):e0487322. PubMed ID: 37184411
[TBL] [Abstract][Full Text] [Related]
15. [Surveillance of resistance in the intensive care units using a cumulative antibiogram].
Yürüyen C; Daldaban Dinçer Ş; Yanılmaz Ö; Boz ES; Aksaray S
Mikrobiyol Bul; 2018 Oct; 52(4):329-339. PubMed ID: 30522419
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
Zhang Y; Lin X; Bush K
J Antibiot (Tokyo); 2016 Aug; 69(8):600-4. PubMed ID: 27353166
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.
Seifert H; Stefanik D; Sutcliffe JA; Higgins PG
Int J Antimicrob Agents; 2018 Jan; 51(1):62-64. PubMed ID: 28705668
[TBL] [Abstract][Full Text] [Related]
20. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
